A meta-analysis of more than 20 phase 3 trials found no clear survival differences by sex or age in metastatic NSCLC but ...
Metastasis-directed therapy (MDT) significantly improved outcomes in patients with oligometastatic prostate cancer, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results